Craig-Hallum analyst Kevin Ellich raised his price target for BioScrip to $3.50 and maintains a Buy rating on the shares. The stock is down due to an internal accounting review that could delay the annual report filing, but the company's Q4 results were better than expected, highlighted by significant gross margin expansion and solid free cash flow, Ellich tells investors in a post-earnings research note. The analyst thinks the company's adjusted EBITDA guidance could prove to be conservative. He admits, though, that it may "take time for the dust to settle" regarding the internal accounting review.